Basic Information
LncRNA/CircRNA Name | PVT1 |
Synonyms | PVT1, LINC00079, MYC, NCRNA00079, onco-lncRNA-100 |
Region | GRCh38_8:127794533-128101253 |
Ensemble | ENSG00000249859 |
Refseq | NR_003367 |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | apoptosis | Drug | ||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | prostate cancer |
ICD-0-3 | C61.9 |
Methods | qPCR, RNAi |
Sample | prostate cancer tissues, cell lines (BPH-1, PNT2, LNCaP, PC-3, and DU145) |
Expression Pattern | up-regulated |
Function Description | PVT1 was overexpressed in prostate cancer tissues and cells. Higher levels of PVT1 indicated poorer overall survival and disease-free survival. A significant association was found between PVT1 expression and tumor stage.PVT1 knockdown significantly inhibited prostate cancer growth in vivo and in vitro and promoted cell apoptosis. PVT1 knockdown also significantly upregulated the expression of cleaved caspase-3 and cleaved caspase-9, but downregulated the expression of c-Myc in prostate cancer cell lines. |
Pubmed ID | 29050519 |
Year | 2017 |
Title | LncRNA PVT1 predicts prognosis and regulates tumor growth in prostate cancer. |
External Links
Links for PVT1 | GenBank HGNC NONCODE |
Links for prostate cancer | OMIM COSMIC |